Skip to main content
OpenTrials
Completed

NCT Number: NCT01257607

Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

The objective of this study is to compare the safety and efficacy of 1% MIM-D3 and 5% MIM-D3 to placebo for the treatment of the signs and symptoms of dry eye.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dry Eye Dry Eye Syndromes Eye Diseases Lacrimal Apparatus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Ora, Inc.

Andover, Massachusetts, 01830, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be at least 18 years of age
  • Provide written informed consent
  • Have a reported history of dry eye
  • Have a history of use or desire to use eye drops for dry eye

Exclusion criteria

  • Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation (e.g. follicular conjunctivitis) at Visit 1, or have been diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or conjunctiva, within the last 12 months
  • Have any planned ocular and/or lid surgeries over the study period
  • Have corrected visual acuity greater than or equal to +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1
  • Have an uncontrolled systemic disease
  • Be a woman who is pregnant, nursing or planning a pregnancy
  • Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study
  • Have a known allergy and/or sensitivity to the test article or its components
  • Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
  • Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days of Visit 1
  • Be unable or unwilling to follow instructions, including participation in all study assessments and visits

Treatment and study plan

MIM-D3 Ophthalmic Solution

Drug

28 Days, BID

Placebo Ophthalmic Solution

Drug

28 Days, BID

Primary outcomes

  1. Corneal staining

    Time frame: 28 days

    Ocular surface damage

Secondary outcomes

  1. Tear film break-up time

    Time frame: 42 days

  2. Conjunctival redness

    Time frame: 42 days

  3. Tear osmolarity

    Time frame: 42 days

Sponsors and collaborators

Lead sponsor

Mimetogen Pharmaceuticals USA, Inc.

Industry

Registry information

Official study title

A Phase 2, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1% MIM-D3 and 5% MIM-D3 Ophthalmic Solutions in the Environment, and During Challenge in the Controlled Adverse Environmental (CAE) Model

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Dec 9, 2010
Registry last updated
Aug 19, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.